Regeneron Pharmaceuticals
Market Cap
US$39.0b
Last Updated
2020/01/23 23:54 UTC
Data Sources
Company Financials +
Executive Summary
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.
Rewards
Risk Analysis
No risks detected for REGN from our risk checks.
Snowflake Analysis
Flawless balance sheet and fair value.
Similar Companies
Share Price & News
How has Regeneron Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: REGN has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-7.5%
REGN
-1.9%
US Biotechs
-0.09%
US Market
1 Year Return
-12.6%
REGN
11.2%
US Biotechs
23.9%
US Market
Return vs Industry: REGN underperformed the US Biotechs industry which returned 10.9% over the past year.
Return vs Market: REGN underperformed the US Market which returned 24.7% over the past year.
Shareholder returns
| REGN | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.5% | -1.9% | -0.09% |
| 30 Day | -5.3% | -2.6% | 3.1% |
| 90 Day | 16.5% | 14.9% | 10.4% |
| 1 Year | -12.6%-12.6% | 12.2%11.2% | 26.6%23.9% |
| 3 Year | 4.7%4.7% | 26.5%22.4% | 50.9%41.2% |
| 5 Year | -14.0%-14.0% | 2.5%-2.3% | 78.1%58.5% |
Price Volatility Vs. Market
How volatile is Regeneron Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 hours ago | Simply Wall St
If You Had Bought Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Five Years Ago, You'd Be Sitting On A 14% Loss, Today2 weeks ago | Simply Wall St
Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) ROE Of 20% Impressive?1 month ago | Simply Wall St
Have Insiders Been Selling Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares?Valuation
Is Regeneron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
3.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: REGN ($363.71) is trading below our estimate of fair value ($367.84)
Significantly Below Fair Value: REGN is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: REGN is good value based on its PE Ratio (18.5x) compared to the Biotechs industry average (19.5x).
PE vs Market: REGN is good value based on its PE Ratio (18.5x) compared to the US market (19x).
Price to Earnings Growth Ratio
PEG Ratio: REGN is poor value based on its PEG Ratio (4.7x)
Price to Book Ratio
PB vs Industry: REGN is overvalued based on its PB Ratio (4x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Regeneron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
4.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: REGN's forecast earnings growth (4.2% per year) is above the savings rate (1.7%).
Earnings vs Market: REGN's earnings (4.2% per year) are forecast to grow slower than the US market (14.3% per year).
High Growth Earnings: REGN's earnings are forecast to grow, but not significantly.
Revenue vs Market: REGN's revenue (5.1% per year) is forecast to grow slower than the US market (7.5% per year).
High Growth Revenue: REGN's revenue (5.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: REGN's Return on Equity is forecast to be high in 3 years time (20.3%)
Next Steps
Past Performance
How has Regeneron Pharmaceuticals performed over the past 5 years?
36.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: REGN has high quality earnings.
Growing Profit Margin: REGN's current net profit margins (28.1%) are lower than last year (28.2%).
Past Earnings Growth Analysis
Earnings Trend: REGN's earnings have grown significantly by 36.6% per year over the past 5 years.
Accelerating Growth: REGN's earnings growth over the past year (19.3%) is below its 5-year average (36.6% per year).
Earnings vs Industry: REGN earnings growth over the past year (19.3%) underperformed the Biotechs industry 103.3%.
Return on Equity
High ROE: REGN's Return on Equity (20.4%) is considered high.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Regeneron Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: REGN's short term assets ($7.1B) exceed its short term liabilities ($1.8B).
Long Term Liabilities: REGN's short term assets ($7.1B) exceed its long term liabilities ($1.7B).
Debt to Equity History and Analysis
Debt Level: REGN is debt free.
Reducing Debt: REGN has no debt compared to 5 years ago when its debt to equity ratio was 11.2%.
Debt Coverage: REGN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: REGN has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: REGN has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if REGN's debt is covered by short term assets.
Next Steps
Dividend
What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of REGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Regeneron Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
3.4yrs
Average management tenure
CEO
Leonard Schleifer (66yo)
32yrs
Tenure
US$26,520,555
Compensation
Dr. Leonard S. Schleifer, M.D., Ph.D., founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron P ...
CEO Compensation Analysis
Compensation vs Market: Leonard's total compensation ($USD26.52M) is above average for companies of similar size in the US market ($USD10.76M).
Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.4yrs
Average Tenure
59yo
Average Age
Experienced Management: REGN's management team is considered experienced (3.4 years average tenure).
Board Age and Tenure
22.0yrs
Average Tenure
68.5yo
Average Age
Experienced Board: REGN's board of directors are seasoned and experienced ( 22 years average tenure).
Insider Trading
Insider Buying: REGN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 7,364 |
| Max Price | US$341.38 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,000 |
| Max Price | US$340.44 |
| Entity | Company |
| Shares | 172,904 |
| Max Price | US$281.15 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,000 |
| Max Price | US$305.93 |
| Entity | Company |
| Shares | 131,115 |
| Max Price | US$412.17 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Leonard Schleifer (66yo)
Co-Founder
- Tenure: 32yrs
- Compensation: US$26.52m
George Yancopoulos (59yo)
Founding Scientist
- Tenure: 19yrs
- Compensation: US$25.38m
Joe LaRosa (60yo)
Executive VP
- Tenure: 8.3yrs
- Compensation: US$3.38m
Marion McCourt (59yo)
Senior VP & Head of Commercial
- Tenure: 1.9yrs
- Compensation: US$10.28m
Bob Landry (55yo)
Executive VP of Finance & CFO
- Tenure: 6.3yrs
- Compensation: US$9.36m
Beth Levine (55yo)
Senior VP
- Tenure: 1yrs
Daniel Van Plew (46yo)
Executive VP and GM of Industrial Operations & Product Supply
- Tenure: 11.8yrs
- Compensation: US$9.01m
Sally Paull
Senior Vice President of Human Resources
- Tenure: 3.8yrs
Hala Mirza
Senior Vice President of Corporate Communications & Citizenship
- Tenure: 1yrs
Justin Holko
Vice President of Investor Relations
- Tenure: 0.6yrs
Board Members
Chris Poon (67yo)
Independent Director
- Tenure: 9.2yrs
- Compensation: US$1.23m
Pindaros Vagelos (89yo)
Chairman of the Board
- Tenure: 25yrs
- Compensation: US$6.35m
Leonard Schleifer (66yo)
Co-Founder
- Tenure: 32yrs
- Compensation: US$26.52m
George Yancopoulos (59yo)
Founding Scientist
- Tenure: 19yrs
- Compensation: US$25.38m
Art Ryan (76yo)
Independent Director
- Tenure: 17yrs
- Compensation: US$1.23m
Michael Brown (78yo)
Independent Director
- Tenure: 28.6yrs
- Compensation: US$1.23m
Joseph Goldstein (79yo)
Independent Director
- Tenure: 28.6yrs
- Compensation: US$1.22m
George Sing (70yo)
Independent Director
- Tenure: 32yrs
- Compensation: US$1.23m
Marc Tessier-Lavigne (59yo)
Independent Director
- Tenure: 8.2yrs
- Compensation: US$1.21m
Bonnie Bassler (57yo)
Independent Director
- Tenure: 3.3yrs
- Compensation: US$1.22m
Company Information
Regeneron Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Regeneron Pharmaceuticals, Inc.
- Ticker: REGN
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$38.985b
- Shares outstanding: 109.32m
- Website: https://www.regeneron.com
Number of Employees
Location
- Regeneron Pharmaceuticals, Inc.
- 777 Old Saw Mill River Road
- Tarrytown
- New York
- 10591
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| REGN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Apr 1991 |
| RGO | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 1991 |
| REGN | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Apr 1991 |
| 0R2M | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Apr 1991 |
| REGN * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Apr 1991 |
| REGN | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Apr 1991 |
| RGO | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Apr 1991 |
| REGN34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 1 REP 0.2 COM USD0.001 | BR | BRL | May 2019 |
Biography
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/23 23:54 |
| End of Day Share Price | 2020/01/23 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.